Biblio

Export 3292 results:
Author Title [ Type(Desc)] Year
Journal Article
I. van Steenoven, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., Kramberger, M. G., Bonanni, L., and Lemstra, A. W., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
D. Renard, Gabelle, A., Hirtz, C., Demattei, C., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1291-1295, 2016.
R. Santangelo, Cecchetti, G., Bernasconi, M. Paola, Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comi, G., and Magnani, G., “Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease.”, J Alzheimers Dis, vol. 60, no. 1, pp. 183-200, 2017.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
K. Kawamura, Miyajima, M., Nakajima, M., Kanai, M., Motoi, Y., Nojiri, S., Akiba, C., Ogino, I., Xu, H., Kamohara, C., Yamada, S., Karagiozov, K., Ikeuchi, T., Kondo, A., and Arai, H., “Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 83, no. 1, pp. 179-190, 2021.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., “Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
C. Gervaise-Henry, Watfa, G., Albuisson, E., Kolodziej, A., Dousset, B., Olivier, J. - L., Jonveaux, T. Rivasseau, and Malaplate-Armand, C., “Cerebrospinal Fluid Aβ42/Aβ40 as a Means to Limiting Tube- and Storage-Dependent Pre-Analytical Variability in Clinical Setting.”, J Alzheimers Dis, vol. 57, no. 2, pp. 437-445, 2017.
S. Wolfsgruber, Polcher, A., Koppara, A., Kleineidam, L., Frölich, L., Peters, O., Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F., and Wagner, M., “Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 58, no. 3, pp. 939-950, 2017.
A. P. Ingber, Hassenstab, J., Fagan, A. M., Benzinger, T. L. S., Grant, E. A., Holtzman, D. M., Morris, J. C., and Roe, C. M., “Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.”, J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
C. B. Malpas, Saling, M. M., Velakoulis, D., Desmond, P., Hicks, R. J., Zetterberg, H., Blennow, K., and O'Brien, T. J., “Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.”, J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
M. Bjerke and Engelborghs, S., “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
A. Rivero-Santana, Ferreira, D., Perestelo-Pérez, L., Westman, E., Wahlund, L. - O., Sarría, A., and Serrano-Aguilar, P., “Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.”, J Alzheimers Dis, vol. 55, no. 2, pp. 625-644, 2017.
L. Parnetti and Eusebi, P., “Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment.”, J Alzheimers Dis, vol. 64, no. s1, pp. S281-S287, 2018.
L. Calderón-Garcidueñas, Avila-Ramírez, J., Calderón-Garcidueñas, A., González-Heredia, T., Acuña-Ayala, H., Chao, C. - K., Thompson, C., Ruiz-Ramos, R., Cortés-González, V., Martínez-Martínez, L., García-Pérez, M. Alberto, Reis, J., Mukherjee, P. S., Torres-Jardón, R., and Lachmann, I., “Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.”, J Alzheimers Dis, vol. 54, no. 2, pp. 597-613, 2016.
S. Abu-Rumeileh, Mometto, N., Bartoletti-Stella, A., Polischi, B., Oppi, F., Poda, R., Stanzani-Maserati, M., Cortelli, P., Liguori, R., Capellari, S., and Parchi, P., “Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.”, J Alzheimers Dis, vol. 66, no. 2, pp. 551-563, 2018.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
A. Arighi, Di Cristofori, A., Fenoglio, C., Borsa, S., D'Anca, M., Fumagalli, G. Giulio, Locatelli, M., Carrabba, G., Pietroboni, A. Margherita, Ghezzi, L., Carandini, T., Colombi, A., Scarioni, M., De Riz, M. Alessandra, Serpente, M., Rampini, P. Maria, Scarpini, E., and Galimberti, D., “Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?”, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
N. P. Rocha, Toledo, A., Corgosinho, L. T. S., de Souza, L. C., Guimarães, H. C., Resende, E. P. F., Braz, N. F. T., Gomes, K. B., Silva, A. C. Simoes E., Caramelli, P., and Teixeira, A. L., “Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer's Disease.”, J Alzheimers Dis, vol. 64, no. 4, pp. 1085-1090, 2018.

Pages